ALXN1102

ALXN1102 (also known as TT30) is a recombinant fusion protein developed as a specific inhibitor of the alternative pathway of the complement system. It was designed to act as an anti-inflammatory and immunosuppressive agent by inhibiting complement activation, which plays a role in various immune-mediated diseases. The drug was originally developed by Taligen Therapeutics and later advanced by Alexion AstraZeneca Rare Disease (a subsidiary of AstraZeneca). Its primary indication under investigation was paroxysmal nocturnal hemoglobinuria (PNH), with additional interest in inflammation and macular degeneration. Clinical development reached phase 1 but has not progressed further[1][3][4].

Other names

ALXN-1103ALXN1103ALXN 1103